Physician profile
Peter James Longo
NPI 1801991666
$1,799.85
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.57 · 2020: $657 · 2021: $834 · 2022: $272 · 2023: $12.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $320.74 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $187.11 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $176.24 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.05 | 2020-2022 | |
| Abbvie INC. | $164.76 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $130.87 | 2019-2021 | |
| Allergan, INC. | $126.51 | 2020 | |
| Amgen INC. | $105.18 | 2020-2022 | |
| Pfizer INC. | $83.41 | 2020-2022 | |
| Esperion Therapeutics, INC. | $64.87 | 2020 | |
| Merck Sharp & Dohme LLC | $58.94 | 2021-2022 | |
| Glaxosmithkline, LLC. | $46.22 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $35.17 | 2020-2021 | |
| Amarin Pharma, INC. | $34.26 | 2019-2021 | |
| Eisai INC. | $21.21 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $20.98 | 2020 | |
| Astellas Pharma US INC | $19.91 | 2020 | |
| Boston Scientific Corporation | $18.32 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Longo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.